CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.

News Chongqing Pharscin Pharmaceutical Co., Ltd.

Equities

002907

CNE100003308

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
13.35 ^CNY	+0.68%		+4.62%	-13.59%

Apr. 03	Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets	MT
Jan. 24	Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 09	CI
Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets	Apr. 03	MT
Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period	Jan. 24	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Pharscin Pharmaceutical Gets FDA Nod on Buspirone Hydrochloride Tablets	23-10-12	MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) added to S&P Global BMI Index	23-09-18	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-20	CI
Pharscin Pharmaceutical Gets Nod to Amend Usage of Bawei Qilong Granules	23-08-18	MT
Pharscin Pharma's Production Base Passes US FDA Inspection	23-07-12	MT
Pharscin Pharma Gets Approval for Supplementary Application of Traditional Chinese Medicine	23-06-12	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Implements Final Cash Dividend of A shares for 2022, Payable on June 13, 2023	23-06-05	CI
Chongqing Pharscin Pharmaceutical Co., Ltd Approves the Cash Dividend for 2022	23-05-22	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Pharscin Pharma Obtains China Marketing Rights to Hypertension Drug; Shares Drop 4%	23-02-20	MT
Pharscin Pharma’s Profit Rises 3.5% in 2022 Despite 7% Drop in Revenue	23-02-13	MT
Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption	23-01-04	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-16	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Announces Final Profit Distribution on A Shares for the Year 2021, Payable on July 14, 2022	22-07-06	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Approves 2021 Profit Distribution Plan	22-05-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Chongqing Pharscin Pharmaceutical Co., Ltd.

Equities

002907

CNE100003308

Summary

Filters